Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism
NCT04648969Phase 2Completed
- Start
- May 2019
- Primary completion
- Aug 2025
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of kisspeptin 112-121 in hypogonadotropic hypogonadism (HH). Primary endpoint: Average Change in Luteinizing Hormone (LH) Pulse Amplitude in Response to Kisspeptin at 52 hours. Started May 2019; status: completed.
02
Drugs
kisspeptin 112-121
03
Conditions
hypogonadotropic hypogonadism (HH)
Beyond the preview
Go deeper on NCT04648969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04648969.